Related Experiment Video
Updated: Jun 29, 2025
Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy
Published on: November 8, 2016
GD3 ganglioside is a promising therapeutic target for glioma patients
Victoria Hein1, Nathalie Baeza-Kallee1,2, Alexandre Bertucci1,3
1Aix-Marseille Université, CNRS, INP, Inst Neurophysiopathol, GlioME Team, Marseille, France.
Abstract:
Glioblastoma is the most frequent and aggressive primary brain tumor in adults. Currently, no curative treatment is available. Despite first-line treatment composed by the association of surgery, radiotherapy, and chemotherapy, relapse remains inevitable in a median delay of 6 to 10 months. Improving patient management and developing new therapeutic strategies are therefore a critical medical need in neuro-oncology. Gangliosides are sialic acid-containing glycosphingolipids, the most abundant in the nervous system, representing attractive therapeutic targets. The ganglioside GD3 is highly expressed in neuroectoderm-derived tumors such as melanoma and neuroblastoma, but also in gliomas. Moreover, interesting results, including our own, have reported the involvement of GD3 in the stemness of glioblastoma cells. In this review, we will first describe the characteristics of the ganglioside GD3 and its enzyme, the GD3 synthase (GD3S), including their biosynthesis and metabolism. Then, we will detail their expression and role in gliomas. Finally, we will summarize the current knowledge regarding the therapeutic development opportunities against GD3 and GD3S.
Insights
Glioblastoma treatment needs improvement. This review explores ganglioside GD3 and GD3 synthase as potential therapeutic targets for aggressive brain tumors, focusing on their role in glioblastoma stemness.
Area of Science:
- Neuro-oncology
- Biochemistry
- Cancer Biology
Background:
- Glioblastoma is an aggressive primary brain tumor with no cure, necessitating novel therapeutic strategies.
- Gangliosides, particularly GD3, are abundant in the nervous system and implicated in glioblastoma stemness.
- GD3 and its synthesizing enzyme, GD3 synthase (GD3S), are potential targets for glioblastoma treatment.
Purpose of the Study:
- To review the characteristics, biosynthesis, and metabolism of GD3 and GD3S.
- To detail the expression and role of GD3 and GD3S in gliomas.
- To summarize therapeutic development opportunities targeting GD3 and GD3S in glioblastoma.
Main Methods:
- Literature review of scientific publications on GD3, GD3S, and gliomas.
- Analysis of GD3 and GD3S expression patterns in glioma tissues.
- Evaluation of the role of GD3 in glioblastoma stem cell biology.
- Summary of preclinical and clinical studies on GD3-targeted therapies.
Main Results:
- GD3 is highly expressed in neuroectoderm-derived tumors, including gliomas.
- GD3 plays a significant role in maintaining glioblastoma stemness.
- GD3 synthase (GD3S) is involved in GD3 biosynthesis and is a critical enzyme in this pathway.
- Targeting GD3 and GD3S presents promising therapeutic avenues for glioblastoma.
Conclusions:
- GD3 and GD3S are crucial players in glioblastoma pathogenesis and stemness.
- Targeting GD3 and GD3S offers a promising strategy for developing new glioblastoma treatments.
- Further research into GD3-targeted therapies is warranted to improve patient outcomes in neuro-oncology.
